Trials / Completed
CompletedNCT02557646
An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis C
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 697 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this open-label, non-randomized, single-arm, multicentre observational study is to investigate the influence of the cumulative dose (total administered dose/ planned dose) of ribavirin on the sustained virologic response (SVR) in participants who have been receiving combination therapy with pegylated interferon alfa-2a (Pegasys) and ribavirin (Copegus).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Peginterferon alfa-2a | Participants received pegylated interferon subcutaneous injection in accordance with current guidelines and SPCs.P |
| DRUG | Ribavirin | Participants received ribavirin 200 mg film-coated tablet in accordance with current guidelines and SPCs. |
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2014-03-01
- Completion
- 2014-03-01
- First posted
- 2015-09-23
- Last updated
- 2016-03-28
- Results posted
- 2016-02-10
Locations
27 sites across 1 country: Hungary
Source: ClinicalTrials.gov record NCT02557646. Inclusion in this directory is not an endorsement.